adaptive combination | |

adaptive graph-based multiple | |

adaptive LASSO | |

adaptive strategy | |

adjusted significance level | |

assessment of randomisation procedures | |

Bayesian decision theory | |

biased corrected test (likelihood ratio test) | |

biasing policy | |

BIC criterion | |

blocked ANOVA | |

bootstrap (constrained parametric bootstrap procedure) | |

causal inference | |

CorrMixed | |

decision theoretic aspect (Bayesian decision theoretic) | |

dOFV (delta objective function values) | |

dose-response | |

EffectTreat | |

ERDO (evaluation of randomisation procedures for design optimisation) | |

similarity of dose response | |

FDR (false discovery rate) | |

first-in-human | |

Fisher information matrix | |

SLOPE (group SLOPE, geneSLOPE) | |

k-means | |

linked assessment criterion | |

many-to-one | |

maximum likelihood estimation | |

MC-AGQ | |

MC-HMC | |

MCPMod (closed MCPMod) | |

confidence bands for difference of curves | |

meta-analysis | |

meta-analytic paradigma | |

mixed effects model | |

MIXFIM | |

model averaging | |

model selection | |

monte-carlo | |

stochastic simulation | |

non-parametric | |

open-label | |

optimal-design (compound D-optimality criterion) | |

parametric power estimation | |

permutation test | |

PESEL (penalized semi-integrated likelihood method) | |

pharmacometrics | |

prior information | |

randomisation based inference | |

randomizeR | |

real world data | |

Robustness | |

SIR (sampling importance resampling) | |

scepticism factor (scepticism) | |

selection bias | |

sequential analysis | |

Simulation | |

SPF (surrogate predictive function) | |

stratification | |

personalised medicine | |

SURROGATE | |

TestingSimilarity | |

threshold-crossing | |

time trend bias | |

two-stage adaptive design | |

type-I-error probability | |

intersection-union principle |